540 related articles for article (PubMed ID: 22954177)
1. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Podda G; Constantinescu CS
Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
[TBL] [Abstract][Full Text] [Related]
2. Cannabis and multiple sclerosis.
Fragoso YD; Carra A; Macias MA
Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
Tanasescu R; Constantinescu CS
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1219-28. PubMed ID: 23621668
[TBL] [Abstract][Full Text] [Related]
4. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
5. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
6. The use of medical-grade cannabis in patients non-responders to Nabiximols.
Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
[No Abstract] [Full Text] [Related]
7. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
9. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Chan A; Silván CV
Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
[TBL] [Abstract][Full Text] [Related]
14. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Nielsen S; Germanos R; Weier M; Pollard J; Degenhardt L; Hall W; Buckley N; Farrell M
Curr Neurol Neurosci Rep; 2018 Feb; 18(2):8. PubMed ID: 29442178
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Haupts MR; Essner U; Mäurer M
Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
[TBL] [Abstract][Full Text] [Related]
17. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
18. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Wade DT; Makela P; Robson P; House H; Bateman C
Mult Scler; 2004 Aug; 10(4):434-41. PubMed ID: 15327042
[TBL] [Abstract][Full Text] [Related]
19. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
20. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
